Key result
Immune checkpoint inhibitor-induced myocarditis typically occurs within ~30-60 days with higher mortality than conventional myocarditis.
Why the study?
Immune checkpoint inhibitor-induced myocarditis is a severe cardiovascular complication of cancer therapy that differs substantially from conventional myocarditis in pathophysiology, presentation, diagnosis, and management.
This review highlights the distinct pathophysiological, clinical, diagnostic, and therapeutic divergences between immune checkpoint inhibitor-induced myocarditis and conventional myocarditis, emphasizing the need for advanced imaging, prompt high-dose immunosuppression, and dedicated cardio-oncology pathways.
Answers are grounded in this paper and cite their sources.
Requires early suspicion and immunosuppression despite preserved LVEF; leaves open prospective validation of tailored diagnostics.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but have introduced immune-related adverse events, among which ICI-induced myocarditis (ICI-M) is one of the most severe cardiovascular complication. Compared with conventional myocarditis (CM), ICI-M is a distinct entity characterized by a hyper-acute, T-cell-mediated autoimmune response due to loss of immune tolerance. While CM typically follows a viral or autoimmune trigger and often evolves toward resolution, ICI-M occurs early after treatment initiation (within 30-60 days) and is associated with high mortality and a significant burden of major adverse cardiovascular events. Clinical presentation differs substantially. CM commonly presents with chest pain and progressive myocardial dysfunction, whereas ICI-M often manifests with non-specific symptoms such as fatigue and carries a higher risk of early conduction abnormalities and malignant arrhythmias. Diagnosis is challenging, as conventional imaging may underestimate disease severity in ICI-M: left ventricular ejection fraction is often preserved and late gadolinium enhancement may be absent in early stages. Advanced techniques, including global longitudinal strain and cardiac magnetic resonance parametric mapping, are therefore crucial for early detection. Diagnosis of ICI-induced myocarditis may also be challenging because of symptom and biomarker overlap with other immune-related adverse events, particularly myositis. Non-specific manifestations and concomitant elevations of troponin and skeletal muscle injury markers can complicate early recognition and differential diagnosis. Management strategies reflect these differences: CM is generally treated with supportive approaches, whereas ICI-M requires immediate discontinuation of ICIs and prompt high-dose immunosuppression. Despite advances, prognosis remains worse in ICI-M, underscoring the need for early recognition and dedicated cardio-oncology pathways.
No takes yet. Share an insight, caveat, or question.
Mistrulli et al. (2026) conducted a review in Immune checkpoint inhibitor-induced myocarditis and conventional myocarditis. Immune checkpoint inhibitors vs. Conventional myocarditis triggers (viral or autoimmune) was evaluated. Immune checkpoint inhibitor-induced myocarditis typically occurs within 30-60 days of treatment initiation and carries higher mortality and arrhythmia risk compared with conventional myocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: